Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: Pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition

Brain Research

Volumn 767, Issue 1, 1997, Pages 45-54

  Psylla, M ^a   Gunther I ^a   Antonini, A ^a   Vontobel, P ^a   Reist, H W ^a   Zollinger, A ^b   Leenders, K L ^a  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

3 O Methyl 6 18F Fluoro L DOPA; 6 18F Fluoro L DOPA ; Aromatic amino acid decarboxylase; Carbidopa; Catechol O methyltransferase; CGP 28014; COMT inhibitors; OR 611; Positron emission tomography; Ro 40 7592

Indexed keywords

6 FLUORODOPA F 18; AMINO ACID DECARBOXYLASE; AMINO ACID DECARBOXYLASE INHIBITOR; CARBIDOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; N (6 OXO 1H PYRID 2 YL) N',N' DIPROPYLFORMAMIDINE; TOLCAPONE; UNCLASSIFIED DRUG; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; FLUORINE; FLUORODOPA F 18;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG MIXTURE; ENZYME ACTIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHESUS MONKEY; ANIMAL; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; MACACA; METABOLISM; STATISTICAL MODEL;

ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BRAIN; CATECHOL O-METHYLTRANSFERASE; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; LINEAR MODELS; MACACA MULATTA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030613624     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00552-0     Document Type: Article

References (50)

1. Bäckström R., Honkanen E., Pippuri A., Kairisalo P., Pystynen J., Heinola K., Nissinen E., Linden I.B., Männistö P.T., Kaakkola S., Pohto P. Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J. Med. Chem. 32:1989;841-846.
2. Barrio J.R., Huang S.C., Phelps M.E. In vivo assessment of neurotransmitter biochemistry in humans. Annu. Rev. Pharmacol. Toxicol. 28:1988;213-230.
3. Bieck P.R., Antonin K.H., Farger G., Nilsson E.B., Schmidt E.K., Dostert P., Strolin-Benedetti M., Waldmeier P.C. Clinical pharmacology of the new COMT inhibitor CGP 28014. Neurochem. Res. 18:1993;1163-1167.
4. Borgulya J., Bruderer H., Bernauer K., Zürcher G., Da Prada M. Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv. Chim. Acta. 72:1989;952-968.
5. 18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. Life Sci. 39:1986;2243-2252.
6. Cedarbaum J.M., Léger G.C., Guttman M. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin. Neuropharmacol. 14:1991;330-342.
7. Chiueh C.C., Zukowska-Grojek Z., Kirk K.L., Kopin I.J. 6-Fluoro-catecholamines as false neurotransmitters. J. Pharmacol. Exp. Ther. 225:1983;529-533.
8. 18F-PET agents. Biochem. Biophys. Res. Commun. 30:1985;1123-1131.
9. 18F]6-fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat. J. Neurochem. 48:1987;601-608.
10. 18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521. Biochem. Pharmacol. 36:1987;2527-2531.
11. 18F-fluorodopa in the hooded rat. Biochem. Pharmacol. 37:1988;247-250.
12. 18F]FDOPA) in humans. J. Cereb. Blood Flow Metab. 13:1993;668-675.
13. M. Da Prada, G. Zürcher, R. Kettler, A. Colzi, New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592, in: G. Bernardi et al. (Eds.), The Basal Ganglia III, Plenum Press, New York, 1990, pp. 723-732.
14. 18F]fluoro-L-DOPA in the rhesus monkey brain. J. Cereb. Blood Flow Metab. 11:1991;726-734.
15. Doudet D.J., McLellan C.A., Aigner T.G., Wyatt R., Cohen R.M. Delayed L-phenylalanine infusion allows for simultaneous kinetic analysis and improved evaluation of specific-to-nonspecific fluorine-18-DOPA uptake in brain. J. Nucl. Med. 33:1992;1383-1389.
16. G. Firnau, R. Chirakal, C. Nahmias, E.S. Garnett, Tracers for the investigation of cerebral presynaptic dopaminergic function with positron emission tomography, in: D. Kuhn (Ed.), Frontiers in Nuclear Medicine: in Vivo Imaging of Neurotransmitter Function in Brain, Heart and Tumors, Am. Coll. Nucl. Phys., Washington, DC, 1991, pp. 67-92.
17. 18F]Fluoro-L-dopa, an analogue of dopa and its use in direct external measurements of storage, degradation and turnover of intracerebral dopamine. Proc. Natl. Acad. Sci. USA. 75:1978;464-467.
18. Guldberg H.C., Marsden C.A. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol. Rev. 27:1975;135-206.
19. 18F]fluoro-L-dopa in rhesus monkey. Nucl. Med. Biol. 22:1995;921-927.
20. Guttman M., Léger G.C., Reches A., Evans A., Kuwabara H., Cedarbaum J.M., Gjedde A. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov. Disord. 8:1993;298-304.
21. Hammerstad J.P., Pate B.D., Hewitt K.A., Chan G.L.Y., Ruth T.J., Calne D.B. The transport of L-6-fluorodopa and its metabolites from blood to cerebrospinal fluid and brain. Ann. Neurol. 34:1993;603-608.
22. Hartvig P., Lindner K.J., Tedroff J., Bjurling P., Hörnfelt K., Långström B. Regional brain kinetics of 6-fluoro-(β-11C)-L-dopa and (β-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography. J. Neural Transm. Gen. Sect. 33:1992;1472-1477.
23. 18F]fluoro-L-DOPA kinetics in positron emission tomography. J. Nucl. Med. 33:1992;1472-1477.
24. Kaakkola S., Wurtman R.J. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J. Neurochem. 60:1993;137-144.
25. Keränen T., Gordin A., Harjola V.P., Karlsson M., Korpela K., Pentikäinen P.J., Rita H., Seppälä L., Wikberg T. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neuropharmacol. 16:1993;145-156.
26. 18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann. Neurol. 20:1986;258-262.
27. 18F]Fluorodopa uptake in brain, in: J.C. Baron et al. (Eds.), Brain Dopaminergic Systems: Imaging with Positron Tomography, Kluwer Academic Publ., Netherlands, 1991, pp. 97-110.
28. Männistö P.T., Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol. Toxicol. 66:1990;317-323.
29. Männistö P.T., Tuomainen P., Tuominen R.T. Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Br. J. Pharmacol. 105:1992;569-574.
30. Männistö P.T., Ulmanen I., Lundström K., Taskinen J., Tenhunen J., Tilgmann C., Kaakkola S. Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. 39:1992;291-350.
31. Martin W.R.W., Palmer M.R., Patlak C.S., Calne D.B. Nigrostriatal function in humans studied with positron emission tomography. Ann. Neurol. 26:1989;535-542.
32. 3H]L-DOPA in rats. Biochem. Pharmacol. 39:1990;1853-1860.
33. 18F]fluoro-L-dopa in rats, monkeys and humans. Life Sci. 47:1990;149-157.
34. 18F]Fluoro-L-DOPA metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J. Cereb. Blood Flow Metab. 11:1991;890-897.
35. 18F]Fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Brain Res. 626:1993;1-13.
36. J.G. Nutt, Pharmacokinetics and pharmacodynamics of levodopa: clinical implications, in: W.C. Koller (Ed.), Handbook of Parkinson's Disease, 2nd ed., Marcel Dekker, New York, 1992, pp. 339-354.
37. Oldendorf W.H. Brain uptake of radiolabeled amino acids, amines and hexoses after arterial injection. Am. J. Physiol. 221:1971;1629-1639.
38. Pate B.D., Snow B.J., Hewitt K.A., Morrison K.S., Ruth T.J., Calne D.B. The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates. J. Nucl. Med. 32:1991;1246-1251.
39. Patlak C.S., Blasberg R.G., Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3:1983;1-7.
40. Patlak C.S., Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 5:1985;584-590.
41. 18F]-fluoro-L-DOPA and its remote routine production for PET investigations of dopaminergic systems. Appl. Radiat. Isot. 44:1993;645-649.
42. 18F]fluoro-dopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J. Neural Transm. Parkinson's Dis. Dementia Sect. 10:1995;91-106.
43. Roberts J.W., Cora-Locatelli G., Bravi D., Amantea M.A., Mouradian M.M., Chase T.N. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology. 43:1993;2685-2688.
44. 18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology. 44:1994;1292-1297.
45. Törnwall M., Männistö P.T. Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission. Pharmacol. Toxicol. 69:1991;64-70.
46. Vingerhoets F.J., Schulzer M., Ruth T., Holden J., Snow B. Reproducibility and discriminating ability of fluorine-18-6-fluorodopa PET in Parkinson's disease. J. Nucl. Med. 37:1996;421-426.
47. Waldmeier P.C., Baumann P.A., Feldtrauer J.J., Hauser K., Bittiger H., Bischoff S., von Sprecher G. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catecholic structure. Naunyn-Schmiedeberg's Arch. Pharmacol. 342:1990;305-311.
48. 18F]-6-L-fluoro-3-O-methyl-L-dopa in the human brain. J. Cereb. Blood Flow Metab. 14:1994;664-670.
49. Ward C.D., Trombley I.K., Calne D.B., Kopin I.J. L-DOPA decarboxylation in chronically treated patients. Neurology. 34:1984;198-201.
50. Zürcher G., Dingemanse J., Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv. Neurol. 60:1993;641-647.